Epsilon M&A Deal Report - Symeres
Transaction Multiples for the Valuation of Private Companies
Private group led by Keensight Capital / Symeres
No EMAT :
120480
Announced Date :
25/05/2021
Type :
LBO (Leverage Buy Out) ,Exit
Deal Value :
Yes
Acquirer :
Private group led by Keensight Capital
Target :
Symeres
Country :
Netherlands
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Created in 2017 by the merger of the CROs Mercachem and Syncom, Symeres, previously known as MercachemSyncom, is a mid-sized European Contract Research Organization for integrated outsourced drug...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
ns | ns | ns | ns |
|
|
| Current |
|
|
ns | ns | ns | ns |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 40
| Date | Acquirer | Target | Country | Multiples | See details |
| 29/06/2022 | Private group led by Cathay Capital | TransCure bioServices | France | *** | 120428 |
| 10/10/2023 | Etap | Syncrosome | France | *** | 120415 |
Source: Epsilon Research / EMAT
